Opendata, web and dolomites

SUMMIT SIGNED

Stepping Up mRNA Mutanome Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SUMMIT project word cloud

Explore the words cloud of the SUMMIT project. It provides you a very rough idea of what is the project "SUMMIT" about.

outgrowth    building    full    heterogeneity    immunotherapy    constraints    mutanome    countermeasures    personalized    immunosuppression    algorithms    lived    mechanisms    mrna    strategies    wave    clonal    first    counteracting    combination    mere    care    nk    trial    clones    vaccinated    interdisciplinary    hallmark    variants    health    technological    industrial    rational    vaccines    mobilizing    unaffected    immune    clinical    drive    antibodies    fundamentally    treatment    solving    preclinical    escape    exhaustion    patients    treatments    cell    moved    realization    potent    universal    inform    neoepitope    tackled    tumor    seamless    human    eliciting    single    vaccine    repertoire    cancers    efficacy    protocols    scarcity    antigen    heterogeneous    point    compatible    spotlight    spectrum    mediated    translation    close    drug    extensive    efficient    unaccounted    ignite    cells    defects    mutations    aberrations    scientific    patient    discovery    pioneered    presentation    disruptive    showed    genetic    memory    vaccination    resistance    prediction    mechanism    cancer    individual    vision    drugs    deciphering    immunity    acute    effector    standards    medical    directed    tumors   

Project "SUMMIT" data sheet

The following table provides information about the project.

Coordinator
TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH 

Organization address
address: FREILIGRATHSTRASSE 12
city: MAINZ
postcode: 55131
website: http://www.tron-mainz.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙482˙500 €
 EC max contribution 2˙482˙500 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH DE (MAINZ) coordinator 2˙482˙500.00

Map

 Project objective

Immunotherapy is expected to fundamentally change the treatment of cancer patients. Personalized vaccines eliciting immune responses against individual cancer mutations have moved into the spotlight. We have pioneered the field and moved ´cancer mutanome vaccines´ from a mere vision into a disruptive medical concept compatible with current standards of drug development and health care practice. Solving key scientific and technological challenges and building on extensive preclinical studies, we showed in a first-in-human trial potent tumor-directed immunity in every single vaccinated patient, and clinical activity of a novel mRNA-based mutanome vaccine. Given that mutations are a hallmark of cancer, mRNA mutanome vaccines are universal drugs the efficacy of which are unaffected by the cancer type. The aim of this proposal is to ignite the next wave of advancement by addressing four key constraints challenging a full clinical realization of such vaccines. We will address the scarcity of point mutations in many tumors by extending neoepitope discovery to the full spectrum of genetic aberrations. Cancers are heterogeneous and outgrowth of clones unaccounted for by the vaccine is an efficient escape mechanism. We will develop neoepitope prediction algorithms deciphering clonal heterogeneity to inform rational vaccine design and countermeasures against selection of target escape variants. Tumor cell resistance to vaccine-induced T cells due to antigen presentation defects will be addressed by developing strategies for mobilizing the full repertoire of immune effector mechanisms, including antibodies and NK cells. T-cell exhaustion will be tackled by vaccination protocols promoting long-lived memory responses and by combination treatments counteracting tumor-mediated immunosuppression. Finally, we will drive the seamless clinical translation of the scientific findings by close interdisciplinary collaboration with strong and established clinical and industrial partners.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUMMIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUMMIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

OAlipotherapy (2018)

Long-retention liposomic drug-delivery for intra-articular osteoarthritis therapy

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

CoolNanoDrop (2019)

Self-Emulsification Route to NanoEmulsions by Cooling of Industrially Relevant Compounds

Read More